MORBIDITY AND SURVIVAL AFTER PERIOPERATIVE CHEMOTHERAPY IN GASTRIC CANCER: A STUDY USING THE BECKER?S CLASSIFICATION AND REGRESSION

• Type: Article in International Scientific Journal
• Date: 2022

Authors

Machado, MCD (Author) Other; Barbosa, JPCDL (Author) Other; de Oliveira, FF (Author) Other; José Barbosa (Author) FMUP

Journal

Title: Arquivos Brasileiros De Cirurgia Digestiva

Vol. 35

ISSN: 0102-6720

Publisher: Colégio Brasileiro de Cirurgia Digestiva

Indexing

ISI Web of Knowledge - 2 Citations

Scopus - 0 Citations

Other information

Authenticus ID: P-00X-RMB

DOI: 10.1590/0102-672020220002e1704

Abstract (EN): BACKGROUND:Gastric cancer is an aggressive neoplasm with a poor prognosis. The multimodal approach with perioperative chemotherapy is currently the recommended treatment for patients with locally advanced gastric cancer. This treatment induces a histopathological response expressed either through the degree of regression of the primary tumor or of the lymph nodes or through yTNM staging. Despite its advantages, there are still doubts regarding the effects of chemotherapy on postoperative morbidity and mortality.AIMS:This study aims to evaluate the impact of perioperative chemotherapy and its effect on anatomopathological results and postoperative morbidity and on patient survival.METHODS:This is an observational retrospective study on 134 patients with advanced gastric cancer who underwent perioperative chemotherapy and curative radical surgery. The degree of histological regression of the primary tumor was evaluated according to Becker's criteria; the proportion of regressed lymph nodes was determined, and postoperative complications were evaluated according to the Clavien-Dindo classification. Survival times were compared between the groups using Kaplan-Meier curves and the Mantel-Cox log-rank test.RESULTS:In all, 22.3% of the patients were classified as good responders and 75.9% as poor responders. This variable was not correlated with operative morbidity (p=1.68); 64.2% of patients had invaded lymph nodes and 46.3% had regressed lymph nodes; and 49.4% had no lymphatic invasion and 61.9% had no signs of venous invasion. Postoperative complications occurred in 30.6% of the patients. The group of good responders had an average survival of 56.0 months and the group of poor responders had 34.0 months (p=0.17).CONCLUSION:Perioperative chemotherapy induces regression in both the primary tumor and lymph nodes. The results of the operative morbidity were similar to those described in the literature. However, although the group of good responders showed better survival, this value was not significant. Therefore, further studies are needed to evaluate the importance of the degree of lymph node regression and its impact on the survival of these patients.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 7